Tirzepatide + Retatrutide
aka Tirz + Reta · Dual-agonist + triple-agonist blend
Mechanism
Pre-mixed metabolic blend combining tirzepatide, a GIP/GLP-1 dual receptor agonist, with retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, both acting on incretin pathways to reduce appetite and improve glucose handling and weight. Tirzepatide is FDA-approved as a finished prescription drug (Mounjaro/Zepbound) but combining it with retatrutide is not an approved use; retatrutide remains investigational in Phase 3 (Eli Lilly TRIUMPH, NDA anticipated late 2026). This specific blend is not an approved product and has no published controlled human efficacy or safety data — any rationale is inferred from the separate agents, and combination-specific human data is lacking.
Studied uses
- Marketed (research only) for weight loss and metabolic support
- Claimed appetite suppression and glycemic improvement
- Research/grey-market interest in overlapping incretin agonism
Identification
| Typical dose | No validated or approved blend protocol exists, and overlapping incretin agonism makes stacking redundant and higher-risk. Component references: tirzepatide 2.5–15 mg once weekly subcutaneous (approved titration); retatrutide ~2–12 mg once weekly subcutaneous in trials. Research use only. |
|---|---|
| Half-life | Component-dependent and not characterized for the mixture. Tirzepatide: ~5 days, supporting once-weekly dosing; retatrutide is likewise engineered for once-weekly dosing. |
Safety
Not FDA-approved as a blend; only tirzepatide is approved as a standalone prescription product, while retatrutide is investigational and research/grey-market when sold loose. Combining two incretin agonists with overlapping GIP/GLP-1 activity offers no established benefit and can compound dose-dependent GI effects (nausea, vomiting, diarrhea) plus risks such as pancreatitis and gallbladder disease; retatrutide's glucagon agonism adds further effects under study. No combination-specific human safety data exists.
Vendors selling Tirzepatide + Retatrutide
No vendor listings on file yet.
Research
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited.
source →Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists.
source →Purpose An increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists.
source →Background Despite the increasing clinical use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), head-to-head evidence across these agents remains limited.
source →Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now used widely to manage diabetes, obesity, and an expanding set of metabolic and cardiorenal conditions.
source →Objective To compare the efficacy and safety of GLP-1 receptor agonists (GLP-1RAs), dual agonists (GLP-1RAs/GIP or GCGR), and retatrutide (GLP-1/GIP/glucagon) for weight loss in adults with overweight or obesity.
source →The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigational agents that are shaping clinical practice.
source →The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
source →The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutid…
source →Medications for obesity have been studied in various populations over the past three decades.
source →The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
source →